Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

by · The Cerbat Gem

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,310,000 shares, an increase of 22.4% from the March 15th total of 1,070,000 shares. Based on an average daily trading volume, of 115,000 shares, the days-to-cover ratio is currently 11.4 days. Approximately 16.7% of the shares of the company are short sold.

Institutional Trading of Karyopharm Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after buying an additional 2,000,000 shares during the period. Jane Street Group LLC raised its position in shares of Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after buying an additional 543,556 shares during the last quarter. Marshall Wace LLP boosted its stake in Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after buying an additional 319,187 shares during the last quarter. Shay Capital LLC purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $116,000. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $85,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KPTI has been the topic of a number of recent analyst reports. HC Wainwright increased their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, Robert W. Baird lowered their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Get Our Latest Report on Karyopharm Therapeutics

Karyopharm Therapeutics Stock Up 12.0 %

NASDAQ KPTI traded up $0.53 on Friday, hitting $4.95. 77,987 shares of the stock were exchanged, compared to its average volume of 81,824. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $18.00. The company has a market cap of $42.42 million, a PE ratio of -4.85 and a beta of 0.58. The company has a 50-day moving average price of $6.24 and a 200-day moving average price of $9.65.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. As a group, equities research analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

(Get Free Report)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Recommended Stories